Placenta – amnion

P-MSC/TERT308

Evercyte ́s P-MSC/TERT308 cell line has been developed from amniotic membrane-derived mesenchymal stromal cells (placental-derived amnion), can be grown without limitations, shows typical markers and functions of MSCs and therefore represents a valuable model for studying processes such as differentiation, inflammation, tissue homeostasis and repair. In recent years evidence has accumulated that the potency of mesenchymal stem cells at least in part is mediated by secreted extracellular vesicles (EVs). P-MSC/TERT308 cell line has been established under conditions that will allow production of EVs for clinical applications.

Print Friendly, PDF & Email

from

€ 1600,–

P-MSC/TERT308
Cat#: CHT-051-0308

ONLY FOR NON PROFIT

FOR PROFIT INDUSTRY

FOR PROFIT-CRO

amniotic membrane

different metabolic activity in placental and reflected regions of the human amniotic membrane

all about our
EV cell factories

interested in production of extracellular vesicles for clinical application?

EVs from placenta-derived cells show high potential in bone tissue engineering

Related Products

Adipose-derived mesenchymal stem cell line ASC/TERT300

Related Services

characterization of extracellular vesicles for functional properties:

testing anti-inflammatory, neo-angiogenic, wound-healing and anti-fibrotic activities

production of extracellular vesicles using hollow fiber bioreactor

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Print Friendly, PDF & Email

from

€ 1300,–

P-MSC/TERT308
Cat#: CHT-051-0308

ONLY FOR NON PROFIT

FOR PROFIT INDUSTRY

FOR PROFIT-CRO